Pharmacist Chronic Kidney Disease On-Demand 1h

The EMPA-KIDNEY trial assessed the efficacy and safety of empagliflozin in patients with chronic kidney disease. This course discusses the results of the trial and its implication on your patients. 

Learning Objectives

Upon successful completion of this application-based course, participants should be able to:
1. Describe the pathophysiology and FDA-approved indications of empagliflozin.
2. Review the current treatment of chronic kidney disease.
3. Discuss the strengths, limitations, and results of the EMPA-KIDNEY trial.
4. Evaluate the role of empagliflozin for the progression of chronic kidney disease.
5. Apply clinical implications of the EMPA-KIDNEY study to a patient case.

Article Information

To obtain 1 contact hour of continuing pharmacy education credit (0.1 CEU), participants must read the article cited below.

The EMPA-KIDNEY Collaborative Group; Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117-127. doi: 10.1056/NEJMoa2204233. Epub 2022 Nov 4. PMID: 36331190; PMCID: PMC7614055.

Faculty

Catherine Gilmore, PharmD

Assistant Professor, Pharmacy Practice
St. Louis College of Pharmacy
University of Health Sciences and Pharmacy

Disclosures:

Catherine Gilmore has no relevant financial relationships with ineligible companies to disclose.

Course Details